# Cannabis and PTSD: Clinical Effects of Cannabinoids > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-ptsd-effects-clinical-review-cannabinoids/ > **Published:** 2026-08-28T17:18:56-04:00 | **Last Modified / Clinically Audited:** 2026-10-14T08:54:47-04:00 > **Clinical Summary:** Cannabis PTSD effects: a systematic review of cannabinoids' clinical impact on PTSD symptoms, revealing mixed outcomes by CUD status and symptom cluster. --- Evidence Watch · CED Clinic Evidence-based synthesis of medical literature for clinical practice. ## Cannabis and PTSD: A Systematic Review This review explores the complex relationship between cannabis use and posttraumatic stress disorder symptoms. Understanding the impact of cannabis on PTSD is crucial for effective treatment strategies. PTSDCannabisSystematic Review ## Study Facts Authors Justyne Rodas, Tony George, Ahmed Hassan Journal The Journal of Clinical Psychiatry Year 2024 Design Systematic review n 14 studies included Intervention Cannabis and cannabinoids use in PTSD patients Comparator Not applicable (varies by study) Primary endpoint Effects on overall PTSD symptoms and symptom clusters Key results with statistics 5 studies suggested benefits, 5 no effect or worsening; 4 studies reported benefits for cluster B and E-related symptoms in non-CUD sample; all 3 studies in comorbid PTSD and CUD sample reported risks of worsening overall symptoms Adverse events Not reported as discrete adverse events (systematic review of existing literature); the review noted risks of worsening suicidal ideation and violent behavior in a subset of studies Funding Not independently verifiable — full-text funding disclosure is behind the publisher paywall and not confirmed via public abstract/summary sources Conflicts of interest Not independently verifiable — full-text COI disclosure is behind the publisher paywall and not confirmed via public abstract/summary sources ## Study Snapshot Study type Systematic review Population Cannabis-using patients with PTSD, both comorbid CUD and non-CUD samples Intervention or exposure Use of cannabis and cannabinoids Comparator Not applicable (varies by study) Primary outcome Effects on PTSD symptoms and symptom clusters Sample size 14 studies included, 3 in comorbid CUD sample, 11 in non-CUD sample Headline result Mixed effects of cannabis use on PTSD symptoms; worsening for those with comorbid CUD This review provides critical insights into how cannabis might affect PTSD symptoms, which can inform clinical decisions and patient care. The systematic review of fourteen studies found mixed evidence on the effects of cannabis use in patients with PTSD. While some studies suggested benefits for overall PTSD symptoms and specific symptom clusters, others reported no effect or worsening of symptoms. In my practice at CED Clinic, this review highlights the need for a personalized approach to treating PTSD with cannabis. The mixed findings suggest that individual responses can vary significantly. Clinicians should consider both potential benefits and risks when recommending cannabis for PTSD patients. Individualized treatment plans are essential given the variability in patient response. **Design:** Not specified **Population:** Not specified **N:** Not specified **Primary Endpoint:** Not specified Evidence Type: [Clinical Research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) Five out of ten studies showed potential benefits for cannabis use on overall PTSD symptoms in patients without comorbid [Cannabis Use Disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) (CUD). However, all three studies involving patients with CUD indicated a worsening of symptoms. No adverse event data was reported in the source study. This review consolidates existing research and provides a comprehensive overview of the current understanding of cannabis’s impact on PTSD. It aligns with previous findings that suggest individual variability in response to cannabis treatment. Alternative interpretations could focus on the quality and design of included studies, suggesting that more rigorous [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) are needed to confirm these preliminary findings. A common misconception is that all patients with PTSD will benefit from cannabis use. This review shows significant variability in outcomes, indicating that individual patient factors play a crucial role. The systematic review included fourteen studies examining the effects of cannabis on PTSD symptoms and symptom clusters among cannabis-using patients with PTSD, including those with comorbid CUD. Limitations include heterogeneity in study designs, sample sizes, and definitions of cannabis use, which may affect the generalizability of findings. Mixed evidence suggests personalized treatment approaches are necessary for using cannabis to manage PTSD symptoms. Photo: Hiếu Lê / Pexels Source & Citation Rodas JD, George TP, Hassan AN. A Systematic Review of the Clinical Effects of Cannabis and Cannabinoids in Posttraumatic Stress Disorder Symptoms and Symptom Clusters. *The Journal of Clinical Psychiatry*. 2024 Feb 14;85(1):23r14862. DOI: [10.4088/JCP.23r14862](https://doi.org/10.4088/JCP.23r14862) · PMID: [38353645](https://pubmed.ncbi.nlm.nih.gov/38353645/) ## CED Clinical Relevance This paper is highly relevant to CED Clinic patients and Dr. Caplan’s practice as it provides a systematic review of the effects of cannabis and cannabinoids on PTSD symptoms in individuals with comorbid [PTSD and cannabis](https://cedclinic.com/cannabis-use-anxiety-young-sexual-minority-women/) use disorder (CUD). This can inform tailored treatment approaches for patients who are using or considering cannabis for symptom management. ## Clinical Insight Clinicians should be cautious when recommending cannabis to patients with both PTSD and CUD, as the review suggests that such patients may experience worsening of overall symptoms. For those without a comorbid CUD diagnosis, the effects on PTSD symptoms are mixed, indicating the need for individualized assessment. ## How This Fits the Broader Conversation This paper contributes to the ongoing debate about the role of cannabis and cannabinoids in managing PTSD symptoms. It highlights the need for more nuanced research that considers the presence or absence of a comorbid [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/), as well as individual differences among patients. ## What This Teaches Us: For Patients and Families This study looks at how using marijuana might help people with post-traumatic stress disorder (PTSD). The results show it can sometimes help reduce symptoms, but for some people who also have problems with marijuana use, it could make things worse. It’s important to talk to a doctor before trying marijuana as a treatment. ## What This Teaches Us: For Clinicians This systematic review highlights that cannabis and cannabinoids may have mixed effects on PTSD symptoms in patients without comorbid [Cannabis Use Disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) (CUD). Clinicians should be aware of potential benefits for some symptom clusters but also the possibility of no effect or worsening of overall PTSD symptoms. In patients with both PTSD and CUD, there is a consistent risk of worsening PTSD symptoms. ## What This Teaches Us: For the Cautious Reader The findings suggest that while cannabis may offer some benefit in reducing specific PTSD symptom clusters, such as those related to avoidance (Cluster B) and hyperarousal (Cluster E), the overall impact on PTSD remains uncertain. The mixed results for overall PTSD symptoms indicate a need for cautious interpretation until further research clarifies these effects. ## Why This Matters: For Policy and Research Readers The inconsistent evidence regarding cannabis use in PTSD suggests that policymakers should consider the potential benefits alongside risks when formulating regulations and coverage policies related to medical cannabis. Public health initiatives may benefit from emphasizing caution, particularly among individuals with comorbid CUD, where worsening of symptoms is a significant risk. ## How Strong Is the Evidence Low The evidence strength is assessed as Low due to the mixed results across studies, variability in study designs (observational and experimental), and limited number of studies examining specific symptom clusters. The presence of both beneficial and detrimental effects without clear patterns reduces confidence in the overall findings. ## Where This Paper Deserves Skepticism This review faces several methodological challenges, including heterogeneity in study design, sample characteristics, and outcome measures. The inclusion criteria did not specify a minimum sample size or quality assessment for individual studies, which could introduce bias. Additionally, the lack of standardized cannabis-related characteristics across studies complicates the interpretation of results. ## What It Does Not Show The review does not provide definitive evidence on the long-term effects of cannabis use in PTSD patients nor does it address specific dosages or types of cannabinoids that may be beneficial or harmful. It also does not account for potential confounding factors such as co-occurring mental health conditions, which could influence outcomes. Photo: Tima Miroshnichenko / Pexels ## What a Careful Reader Should Take Away This systematic review by Rodas, George, and Hassan examines the effects of cannabis and cannabinoids on PTSD symptoms in individuals with or without a comorbid [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) (CUD). The authors conducted a comprehensive search across multiple databases to identify studies published between January 1990 and February 2023. Among the fourteen included studies, five suggested benefits associated with cannabis use for overall PTSD symptoms in non-CUD patients, while another five indicated no effect or worsening of symptoms. For those with comorbid PTSD and CUD, all three studies reported risks of symptom exacerbation. CED Perspective Lens ## Interpreting This Evidence Through Multiple Clinical Perspectives This systematic review examines the clinical effects of cannabis and cannabinoids on PTSD symptoms, revealing mixed outcomes that depend on whether patients have a comorbid cannabis use disorder (CUD). Current Interpretation Cannabis effects on PTSD vary by comorbid CUD status. ### Overview The review highlights the complex relationship between cannabis use and PTSD symptomatology. It underscores the need for nuanced clinical guidance tailored to individual patient profiles, particularly in distinguishing those with and without a comorbid CUD. This work contributes to ongoing debates about the therapeutic potential of cannabinoids while also cautioning against their indiscriminate use due to varying efficacy and risk profiles. The headline conclusion, no major benefit for overall PTSD symptoms, sits alongside a more specific one, real signal for cluster B and E symptoms in patients without comorbid CUD. Both are true simultaneously, and collapsing them into a single yes-or-no verdict on cannabis for PTSD would misrepresent what this review actually found. - Mixed evidence on cannabis benefits for PTSD symptoms - Cannabis may worsen symptoms in patients with comorbid CUD - Potential benefits noted for specific symptom clusters (B, E) - Need for personalized treatment approaches Overview Interpretation The review suggests that the clinical effects of cannabis and cannabinoids on PTSD are context-dependent, requiring careful consideration of individual patient factors. ### Patient Takeaway If you have PTSD without a cannabis use disorder (CUD), some studies suggest that using cannabis might help with your symptoms, but others show no benefit or even worsening of symptoms. However, if you also struggle with CUD, the evidence strongly suggests that cannabis could worsen your PTSD symptoms. It’s crucial to discuss these risks and benefits with a healthcare provider. Even among patients who see benefit, the improvement tends to show up in specific symptom areas, particularly intrusive memories and hyperarousal, rather than across every aspect of PTSD. Expecting cannabis to broadly resolve PTSD is not what this evidence supports, even in the patients who do see some improvement. - Mixed outcomes for non-CUD patients - Potential worsening in comorbid CUD cases - Consider discussing personalized treatment options Patient Perspective Cannabis use for PTSD should be carefully considered, especially if you have a history of cannabis misuse. ### Clinician’s POV Clinicians must consider the patient’s comorbid CUD status when evaluating the potential use of cannabis for PTSD. Documentation should reflect this nuanced approach, including detailed symptom tracking. Reimbursement policies may vary by region and require careful review to ensure compliance with local regulations and institutional guidelines. Given that all three comorbid-CUD studies reported risk of worsening, a CUD screen should precede, not follow, any recommendation around cannabis and PTSD. For patients without CUD, setting expectations around cluster-specific rather than global symptom improvement will likely produce a more accurate conversation than promising general PTSD relief. - Document patient’s comorbid CUD status - Monitor symptoms closely in cannabis-using patients - Review reimbursement policies for cannabinoid treatments Clinician Perspective Clinicians should tailor their approach based on the individual patient’s risk profile and document all decisions carefully. ### A Skeptical Read A 5-of-10 split on overall PTSD symptoms in the non-CUD sample is, functionally, a coin flip. It is worth asking whether the four studies reporting cluster B and E benefits are being given more narrative weight than a fair reading of the full 14-study picture supports, since the review’s own headline conclusion is that it did not find major overall benefits. It is also worth questioning why the comorbid-CUD finding, all three studies reporting risk of worsening, is not more prominent in how this evidence gets summarized publicly. A pattern this consistent across all three available studies in that subgroup is arguably the most confident finding in the entire review, yet it is easy for a headline focused on potential benefit to bury it. Selective attention to the more encouraging cluster-specific findings, while treating the null overall-symptom result and the comorbid-CUD risk finding as footnotes, is a real risk in how this kind of mixed evidence gets communicated to patients and the public. - A 5-of-10 split on overall symptoms is closer to a coin flip than a signal, whatever weight the cluster-specific findings receive in summary. - The comorbid-CUD risk finding (3 of 3 studies) is arguably the review’s most consistent result, yet is easy to underweight in public-facing summaries. - Cluster-specific benefit findings (4 studies) should not be generalized into an overall-benefit narrative the review itself does not support. - Mixed evidence is genuinely mixed; framing it as leaning toward benefit or toward harm both overstate what 14 heterogeneous studies show. Skeptical Interpretation The most consistent finding in this review is risk in comorbid CUD patients, not benefit, and that deserves at least as much attention as the cluster-specific improvements. ### Study Critic Fourteen studies split into two subgroups, 3 comorbid-CUD and 11 non-CUD, is a thin evidentiary base for either subgroup conclusion on its own. The comorbid-CUD conclusion in particular rests on just three studies; a robust, generalizable finding about that population would need substantially more than three data points, however consistent those three happen to be. The review also spans experimental and observational designs pooled together, along with a wide range of cannabis-related characteristics, different products, different dosing, different use patterns, and different psychometric instruments for measuring PTSD symptoms. Combining findings across designs and measurement tools this varied risks comparing outcomes that are not really measuring the same thing. Standard risk-of-bias tools were applied (the review references ROBINS-I and RoB 2 frameworks for non-randomized and randomized studies respectively), which is methodologically appropriate, but the review does not report how many individual studies scored as high risk of bias, making it hard for a reader to judge how much of the 14-study evidence base is actually high quality. - The comorbid-CUD conclusion rests on only 3 studies, too few to be considered a robust, generalizable finding on its own. - Experimental and observational designs, using different cannabis products, dosing, and PTSD measurement instruments, were pooled together. - Formal risk-of-bias tools were applied, but individual study quality scores are not reported in a way that lets readers judge how much of the evidence base is high-risk. - Fourteen studies split across two subgroups leaves each subgroup conclusion resting on a small number of underlying studies. Methodological Interpretation Both subgroup conclusions, and especially the 3-study comorbid-CUD finding, rest on evidence bases too small to treat as settled, whatever direction they point. ### Compared to Past Research Earlier reviews of cannabis and PTSD tended to ask a single blunt question: does cannabis help or hurt PTSD symptoms overall? That framing produced exactly the kind of contradictory, hard-to-interpret literature this 2024 review was built to sort through, gathering studies published from 1990 through February 2023. What distinguishes this review from that earlier body of work is its decision to split the analysis by comorbid CUD status and by PTSD symptom cluster, rather than asking one overall-benefit question. That structural choice is what surfaces the cluster B and E findings and the comorbid-CUD risk pattern, distinctions the older, single-question literature was not designed to detect. This also reflects a broader shift in psychiatric research generally, away from asking whether a treatment works for a diagnosis as a whole and toward asking which specific symptom clusters or patient subgroups respond differently. Applying that more granular lens to cannabis and PTSD is relatively recent, and this review is one of the more systematic applications of it to date. - Earlier literature asked a single overall-benefit question; this review splits by comorbid CUD status and by PTSD symptom cluster instead. - That structural choice is what surfaces the cluster B/E findings and the comorbid-CUD risk pattern that a single-question review would miss. - The shift toward subgroup- and cluster-specific analysis mirrors a broader trend in psychiatric research away from whole-diagnosis treatment questions. - Covering studies from 1990 through February 2023 gives this review one of the longest time horizons applied to this specific question. Historical Interpretation Splitting the analysis by comorbid CUD status and symptom cluster, rather than asking one overall-benefit question, is what let this review find patterns earlier literature was not structured to detect. ### Practical Considerations The single most actionable practical step this review supports is screening for comorbid cannabis use disorder before, not after, a conversation about cannabis and PTSD symptom management. Given that all three comorbid-CUD studies reported risk of worsening, that screening step changes the risk calculus for a meaningful subset of patients. For patients without comorbid CUD, the cluster-specific findings argue for tracking symptoms by cluster rather than relying on a single overall PTSD severity score. A patient whose re-experiencing and hyperarousal symptoms (clusters B and E) improve on cannabis, while other symptom domains stay flat, is a different clinical picture than one where nothing changes, and a single composite score can miss that distinction entirely. None of this requires new technology, but it does require intake and follow-up protocols most practices do not currently have: a CUD screen at intake, and symptom-cluster-level tracking at follow-up rather than a single global PTSD score. - Screen for comorbid cannabis use disorder before recommending or continuing cannabis use for PTSD symptom management. - Track PTSD symptoms by cluster (particularly clusters B and E) rather than relying only on a single composite severity score. - Recognize that a global “no major benefit” headline can obscure real cluster-specific improvement in individual patients. - Build a documented follow-up protocol, since the review found this evidence sensitive to both CUD status and symptom domain. Practical Interpretation Screening for comorbid CUD status and tracking symptoms by cluster, rather than a single global score, are the two protocol changes this review most directly supports. ### Future Directions Future research should focus on larger, more controlled studies to better understand the effects of cannabis on PTSD symptoms. Investigating specific cannabinoid profiles may also provide insights into potential therapeutic mechanisms. Emerging institutional behavior might include more standardized protocols for assessing and monitoring patients using cannabis for PTSD. A particularly useful next step would be prospective studies that track symptom clusters separately from the start, rather than reporting overall PTSD severity and only later breaking out cluster-level findings, since that design choice is what let this review find the B/E signal in the first place. - Larger, controlled studies needed - Investigate specific cannabinoid effects - Standardized assessment protocols Forward Interpretation Future research should aim to clarify the role of cannabinoids in [PTSD treatment](https://cedclinic.com/cannabis-and-ptsd-treatment-memory-loss-benefits/) through larger, more controlled studies. ### Misreadings and Bad-Faith Takes Misinterpretations might claim that cannabis universally improves PTSD symptoms or is safe for all patients. This oversimplification ignores the nuanced findings and potential risks highlighted in the review. It’s important to avoid overgeneralizing the results, as they vary significantly based on comorbid CUD status. A subtler misreading treats the cluster B/E finding as if it applied to all PTSD patients using cannabis. It comes specifically from the non-CUD subgroup; extending it to patients with comorbid cannabis use disorder runs directly against what the same review found in that population. - Avoid universal claims about cannabis benefits - Do not ignore patient-specific risk factors - Prevent oversimplification of findings Misreading Correction Misinterpretations should be corrected to reflect the nuanced and context-dependent effects of cannabis on PTSD. ## Join the Conversation What are your thoughts on the mixed findings regarding cannabis’s impact on PTSD symptoms? Share your insights below! ## Frequently Asked Questions Can cannabis help with my PTSD symptoms? The review shows mixed results. Some studies suggest potential benefits, but others report no effect or worsening of symptoms. It’s important to discuss your individual case with a healthcare provider. What if I have both [PTSD and Cannabis](https://cedclinic.com/cannabis-use-anxiety-young-sexual-minority-women/) Use Disorder (CUD)? Studies involving patients with CUD reported that cannabis use may worsen PTSD symptoms. If you have both conditions, it is crucial to consult with your doctor about alternative treatment options. What were the main findings regarding cannabis use in patients with PTSD but without a comorbid Cannabis Use Disorder (CUD)? The review found that among 10 studies examining overall PTSD symptoms in non-CUD samples, half suggested benefits associated with cannabis use while the other half indicated no effect or worsening of symptoms. Four studies reported potential benefits for cluster B and E-related symptoms. How did the study assess the impact of cannabis on specific symptom clusters of PTSD? The review included studies that used validated measures to evaluate the effects of cannabis use on specific PTSD symptom clusters, such as re-experiencing (Cluster B) and hyperarousal (Cluster E). Four studies reported benefits for these clusters in non-CUD samples. What were the findings for patients with both [PTSD and Cannabis](https://cedclinic.com/cannabis-use-anxiety-young-sexual-minority-women/) Use Disorder (CUD)? All three studies that included cannabis-using patients with comorbid PTSD and CUD found risks associated with worsening of overall PTSD symptoms. Which databases were searched to gather evidence on the effects of cannabis in PTSD? The systematic review conducted a search across PubMed, PsycINFO, and EMBASE databases using terms related to cannabis, cannabinoids, and PTSD. What criteria did studies need to meet for inclusion in this systematic review? Studies were included if they were experimental or observational, conducted on cannabis-using patients with PTSD, used validated measures of PTSD symptoms, and were published in English from January 1990 through February 2023. How many studies were ultimately included in the systematic review? Fourteen studies met the inclusion criteria for this systematic review on the effects of cannabis and cannabinoids on PTSD symptoms and clusters. Did the review find any benefit for specific PTSD symptom clusters? Yes. In the non-CUD sample, four studies reported benefits of cannabis specifically for cluster B (re-experiencing) and cluster E (arousal and reactivity) symptoms, even though the review did not find major benefits for overall PTSD symptom scores across the full set of studies. What are the key limitations of this body of evidence? The authors note that most included studies were observational rather than experimental, involved small and heterogeneous samples, and used inconsistent comparator groups and cannabis-exposure definitions. They conclude that more experimental studies are needed to determine the causal effects of cannabis and cannabinoids on PTSD, meaning the current evidence base cannot establish cause and effect. [1] Authors not resolved from source (n.d.). A Systematic Review of the Clinical Effects of Cannabis and Cannabinoids in Posttraumatic Stress Disorder Symptoms and Symptom Clusters. Journal not resolved from source. Related Reading at CED Clinic Continue exploring the evidence Medical Marijuana Linked to Significant Improvements in Chronic Pain, Anxiety and PTSD [Read the article](https://cedclinic.com/medical-cannabis-chronic-pain-management-benefits/) THC Drug Eliminated Nightmares for Over a Third of PTSD Patients in German Trial [Read the article](https://cedclinic.com/thc-drug-eliminated-nightmares-for-over-a-third-of-ptsd-patients-in-german-trial/) Cannabinoids for Mental Health and Addiction: What 200 Studies Actually Show [Read the article](https://cedclinic.com/cannabinoids-mental-health-addiction-meta-analysis/) [Share on X](https://twitter.com/intent/tweet?text=A%20Systematic%20Review%20of%20the%20Clinical%20Effects%20of%20Cannabis%20and%20Cannabinoids%20in%20Posttraumatic%20Stress%20Disorder%20Symptoms%20and%20Symptom%20Clusters&url=https://cedclinic.com/a-systematic-review-of-the-clinical-effects-of-cannabis-and-cannabinoids-in-post/)[Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https://cedclinic.com/a-systematic-review-of-the-clinical-effects-of-cannabis-and-cannabinoids-in-post/)[Share on BlueSky](https://bsky.app/intent/compose?text=A%20Systematic%20Review%20of%20the%20Clinical%20Effects%20of%20Cannabis%20and%20Cannabinoids%20in%20Posttraumatic%20Stress%20Disorder%20Symptoms%20and%20Symptom%20Clusters%20https://cedclinic.com/a-systematic-review-of-the-clinical-effects-of-cannabis-and-cannabinoids-in-post/)[Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[Read on Substack](https://doctorapprovedcannabis.substack.com/)[Subscribe via RSS](https://cedclinic.com/feed/) Massachusetts Clinical Care & Certification Are you a Massachusetts resident seeking physician-supervised cannabinoid therapy? Learn more about scheduling a telehealth consultation with a certified [Massachusetts medical marijuana doctor](https://cedclinic.com/massachusetts-medical-marijuana-doctor/), or read our step-by-step 2026 guide on [how to get a medical marijuana card in Massachusetts](https://cedclinic.com/how-to-get-a-medical-marijuana-card-in-massachusetts/) to save ~20% on state dispensary taxes. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).